Ovid Therapeutics (STU:1OT) Additional Paid-In Capital : €345.75 Mil(As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Ovid Therapeutics Additional Paid-In Capital?

Ovid Therapeutics's quarterly additional paid-in capital increased from Sep. 2024 (€334.48 Mil) to Dec. 2024 (€355.73 Mil) but then stayed the same from Dec. 2024 (€355.73 Mil) to Mar. 2025 (€345.75 Mil).

Ovid Therapeutics's annual additional paid-in capital declined from Dec. 2022 (€337.74 Mil) to Dec. 2023 (€335.25 Mil) but then increased from Dec. 2023 (€335.25 Mil) to Dec. 2024 (€355.73 Mil).

Ovid Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Ovid Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovid Therapeutics Additional Paid-In Capital Chart

Ovid Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

277.64

310.67

337.74

335.25

355.73

Ovid Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															338.36	343.62	334.48	355.73	345.75

Ovid Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Ovid Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Ovid Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovid Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovid Therapeutics Inc (STU:1OT) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

OVID:USA

Address

441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001

Website

https://www.ovidrx.com

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Ovid Therapeutics Headlines

No Headlines